Reviewer's report

**Title:** Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report

**Version:** 2 **Date:** 23 September 2010

**Reviewer:** Kathryn Ruddy

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: Yes

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

**Comments to authors:**

Minor comments:
-“skin disorders” should be two words in the intro of the abstract
- I might rephrase the final few sentences of the case presentation to make them clearer. After anti-SSB/Ro 5.0U/ml, I would replace "in three months recheck" with "when checked 3 months". I do not understand the meaning of the statement that anti-ENA antibodies were not controlled-- does that mean not checked? Also, instead of just stating that ALK decreased, it would be good to state what it was at max.

**Quality of written English:** Needs some language corrections before being
published

Declaration of competing interests:

I declare that I have no competing interests